ABVD in the treatment of Hodgkin's disease

Valeria Bonfante, Armando Santoro, Simonetta Viviani, Pinuccia Valagussa, Gianni Bonadonna

Research output: Contribution to journalArticlepeer-review

Abstract

This paper summarizes the clinical results achieved at the Milan Cancer Institute in advanced Hodgkin's disease through successive randomized studies performed during the last two decades. Long-term results confirm the therapeutic activity of a regimen containing bleomycin and doxorubicin, such as ABVD (doxorubicin/bleomycin/ vinblastine/dacarbazine), as salvage treatment and as primary chemotherapy, either when combined with radiation or cyclically alternated with MOPP (mechlorethamine/ vincristine/procarbazine/prednisone). Delayed iatrogenic morbidity (namely, sterility and leukemogenesis) was less frequently documented in ABVD-treated patients compared with MOPP-treated patients. Nevertheless, bleomycin- and anthracycline-containing regimens can be refined in the attempt to further decrease iatrogenic toxicity.

Original languageEnglish
Pages (from-to)38-45
Number of pages8
JournalSeminars in Oncology
Volume19
Issue number2 SUPPL. 5
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'ABVD in the treatment of Hodgkin's disease'. Together they form a unique fingerprint.

Cite this